BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

The Mentholatum Company, Inc. Acquires OXY(R) Brand From GlaxoSmithKline (GSK)


10/19/2005 5:12:26 PM

ORCHARD PARK, N.Y., Dec. 13 /PRNewswire/ -- The Mentholatum Company, Inc., a manufacturer and marketer of non-prescription drugs and health care products, has purchased the OXY(R) brand of acne skin care products from GlaxoSmithKline, one of the worlds leading pharmaceutical and consumer healthcare companies. The transaction took place on December 10, 2004 and Mentholatum will immediately begin selling and marketing the entire OXY(R) product line, including OXY(R) Cleansing Pads, OXY(R) Acne Spot Treatments and OXY(R) Acne Washes, worldwide. However, GlaxoSmithKline will continue to distribute the OXY products for a transitional period in most markets on behalf of Mentholatum.

The OXY(R) acquisition is a welcome addition to the Mentholatum line of products that includes WellPatch(TM) pain relieving pads, Softlips(R) Lip Protectant/Sunscreen, Mentholatum(R) Ointment, and Rohto(TM) eye care products. "The OXY(R) family of skincare products is a well established and strong brand in the Acne Segment, an important part of the Dermatology Category," says Dr. Akiyoshi Yoshida, Mentholatum President and CEO. "It adds significant volume to Mentholatum's US business unit and enables us to grow in a way that makes sense for our business and for our consumers, who recognize our products for their quality and value."

This acquisition is a strategic fit to Mentholatum's global business as well. Mentholatum is a wholly-owned subsidiary of Rohto Pharmaceutical Co., Ltd. of Osaka, Japan, one of the 25 largest OTC Companies in the world and an innovative leader in developing and marketing eye care and skin care products. Dr. Yoshida explains, "OXY(R) will give Mentholatum an immediate entry into the US Skin Care Category and provide a strong, globally-recognized brand name under which Rohto products can be introduced to the United States. While OXY(R) products are strong in North America and the UK, the potential for worldwide growth under the Mentholatum umbrella is great."

"Mentholatum is acquiring a strong brand with immediate consumer recognition, 90 percent total brand awareness among the US teen target market, and a great tag line," says Mark Cieslinski, VP Marketing & Sales. "It has a long history -- generations of people know that if you need to get rid of your 'zits,' you just 'OXYCUTE'EM(R)!' The brand has a strong foundation upon which new product development and innovation can drive incremental sales which will give Mentholatum a stronger presence with our key retail partners."

Mentholatum World and US Division Headquarters are in Orchard Park, New York, with divisions in Australia, South Africa, Canada, Scotland, Taiwan, Hong Kong, South Korea, Mexico, Malaysia, Thailand, and China. Manufacturing is performed in 5 locations around the globe and products are marketed and sold in over 130 countries.

For more information on Mentholatum and its brands, visit our web site at http://www.mentholatum.com/.

Mentholatum Company, Inc.

CONTACT: Taffy Collopy, Mentholatum Public Relations, +1-716-677-2500


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->